Fadi Haddad

Peer-Reviewed Articles

1. Senapati J, Jabbour E, Short NJ, Jain N, Haddad F, Bathala T, Kovalenko I, Bidikian A, Ravandi F, Khouri I, Kadia TM, Garris R, Montalban Bravo G, Chien K, Shpall E, Kebriaei P, Kantarjian HM. Liver elastography for risk-assessment of liver toxicity and risk factors for Sinusoidal obstruction syndrome in patients with acute lymphoblastic leukemia receiving inotuzumab ozogamicin. Blood Cancer J 14(1):129, 2024. PMID: 39112504.
2. Haddad FG, Nasnas C, Sasaki K, Paul S, Issa GC, Rausch C, Jabbour E, Kantarjian H. Using Proton Pump Inhibitors is not Associated With Adverse Outcomes in Patients With Chronic Myeloid Leukemia Treated With Dasatinib. Clin Lymphoma Myeloma Leuk 24(7):484-487, 2024. e-Pub 2024. PMID: 38503634.
3. Kantarjian H, Chifotides HT, Haddad FG, Short NJ, Loghavi S, Jabbour E. Ponatinib-review of historical development, current status, and future research. Am J Hematol 99(8):1576-1585. e-Pub 2024. PMID: 38727135.
4. Marvin-Peek J, Jen WY, Kantarjian HM, McCue D, Haddad FG, Weirda W, Ferrajoli A, Burger J, Abusab T, Jorgensen J, Wang SA, Patel K, Loghavi S, O’Brian S, Ravandi F. Long-term results of the sequential combination of cladribine and rituximab in Hairy cell leukemia. Leuk Lymphoma, 2024. PMID: 38749022.
5. Senapati J, Kantarjian HM, Bazinet A, Reville P, Short NJ, Daver N, Borthakur G, Bataller A, Jabbour E, DiNardo C, Haddad F, Saski K, Popat U, Oran B, Alousi AM, Loghavi S, Shpall E, Garcia-Manero G, Ravandi F, Kadia TM. Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation. Cancer, 2024. PMID: 38809547.
6. Haddad FG, Sasaki K, Nasr L, Short NJ, Kadia T, Dellasala S, Cortes J, Nicolini FE, Issa GC, Jabbour E, Kantarjian H. Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase. Cancer, 2024. PMID: 38804723.
7. Jabbour E, Haddad FG, Sasaki K, Carter BZ, Alvarado Y, Nasnas C, Nasr L, Masarova L, Daver N, Pemmaraju N, Short NJ, Skinner J, Kadia T, Borthakur G, Garcia-Manero G, Ravandi F, Issa GC, Andreeff M, Kantarjian H. Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia. American Cancer Society Journals 130(15):2652-2659, 2024.
8. Short NJ, Jabbour E, Nasr LF, Jain N, Haddad FG, Issa GC, Saski K, Senapati J, Kebriaei P, Garris R, Konopleva M, Ravandi F, Kantarjian H. Characteristics and outcomes of patients with relapsed Philadelphia chromosome‐positive acute lymphoblastic leukemia after failure of a frontline ponatinib‐containing therapy in American Journal of Hematology. Am J Hematol 99(7):1423-1426. e-Pub 2024. PMID: 38607091.
9. Kantarjian H, Branford S, Breccia M, Cortes J, Haddad FG, Hochhaus A, Hughes T, Issa GC, Jabbour E, Nicolini FE, Saski K, Xavier-Mahon F. Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia?. Leukemia 38(5):947-950. e-Pub 2024. PMID: 38531949.
10. Senapati J, Kantarjian H, Haddad FG, Short NJ, Welch MA, Jain N, Jabbour E. SOHO State of the Art Updates and Next Questions | Next Questions: Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. e-Pub 2024. PMID: 38195323.
11. Short NJ, Jabbour EJ, Jain N, Senapati J, Nasr LF, Haddad FG, Li Z, Hsiao Y, Yang JJ, Pemmaraju N, Ohanian M, Wierda WG, Montalban-Bravo G Borthakur G, Han L, Xiao L, Huang X, Abramova R, Zhao M, Garris R, Konopleva M, Ravandi F, Kantarjian HM. A Phase 1/2 Study of Mini-Hyper-CVD plus Venetoclax in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Blood Advances, 2024. PMID: 38207208.
12. Senapati J, Kantarjian H, Haddad FG, Short NJ, Welch MA, Jain N, Jabbour E. SOHO State of the Art Updates and Next Questions | Next Questions: Acute Lymphoblastic Leukemia. Elsevier, 2024.
13. Sasaki K, Haddad FG, Short NJ, Jain N, Issa G, Jabbour E, Kantarjian H. Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy-The Surveillance, Epidemiology, and End Results database, 2000-2019. Cancer 129(23):3805-3814, 2023. e-Pub 2023. PMID: 37769040.
14. Haddad FG, Jabbour E, Short NJ, Jain N, Kantarjian H. SOHO State of the Art Updates and Next Questions: Update on the Approach to Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. e-Pub 2023. PMID: 38185587.
15. Short NJ, Jabbour E, Jamison T, Paul S, Cuglievan B, McCall D, Gibson A, Jain N, Haddad FG, Nasr LF, Marx KR, Rausch C, Savoy JM, Garris R, Ravandi F, Kantarjian H. Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. e-Pub 2023. PMID: 38212207.
16. Haddad FG, Short NJ. Treatment discontinuation in chronic myeloid leukemia: When, how, and why?. Am J Hematol 98(11):1670-1672, 2023. e-Pub 2023. PMID: 37753704.
17. Gener-Ricos G, Haddad FG, Sasaki K, Issa GC, Skinner J, Masarova L, Borthakur G, Alvarado Y, Garcia-Manero G, Jabbour E, Kantarjian H. Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results. Clin Lymphoma Myeloma Leuk 23(10):742-748, 2023. e-Pub 2023. PMID: 37308342.
18. Haddad FG, Sasaki K, Bidikian A, Issa GC, Kadia T, Jain N, Alvarado Y, Short NJ, Pemmaraju N, Loghavi S, Patel KP, Kanagal-Shamanna R, Yilmaz M, Masarova L, Jabbour E, Kantarjian H. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era. Am J Hematol 98(10):1619-1626, 2023. e-Pub 2023. PMID: 37485584.
19. Cuglievan B, Connors J, He J, Khazal S, Yedururi S, Dai J, Garces S, Quesada AE, Roth M, Garcia M, McCall D, Gibson A, Ragoonanan D, Petropoulos D, Tewari P, Nunez C, Mahadeo KM, Tasian SK, Lamble AJ, Pawlowska A, Hammond D, Maiti A, Haddad FG, Senapati J, Daver N, Gangat N, Konopleva M, Meshinchi S, Pemmaraju N. Blastic plasmacytoid dendritic cell neoplasm: a comprehensive review in pediatrics, adolescents, and young adults (AYA) and an update of novel therapies. Leukemia 6(53):26, 2023. e-Pub 2023. PMID: 37452102.
20. Haddad FG, Kourie HR, Saleh K. Moving away from chemotherapy in newly diagnosed Philadelphia chromosome-positive B-cell acute lymphoblastic leukaemia. Br J Haematol 202(6):1084-1086, 2023. e-Pub 2023. PMID: 37525325.
21. Short NJ, Jabbour E, Macaron W, Ravandi F, Jain N, Kanagal-Shamanna R, Patel KP, Loghavi S, Haddad FG, Yilmaz M, Issa GC, Kebriaei P, Kornblau SM, Pelletier S, Flores W, Matthews J, Garris R, Kantarjian H. Ultrasensitive NGS MRD assessment in Ph+?ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1. Am J Hematol 98(8):1196-1203, 2023. e-Pub 2023. PMID: 37183966.
22. Haddad FG, Bidikian A, Issa GC. Reply to "Impact of obesity surgery on tyrosine kinase inhibitor responses and survival outcomes in patients with chronic myeloid leukemia: Further data are still warranted!". Cancer 129(14):2268, 2023. e-Pub 2023. PMID: 37138374.
23. Jabbour E, Short NJ, Senapati J, Jain N, Huang X, Daver N, DiNardo CD, Pemmaraju N, Wierda W, Garcia-Manero G, Montalban Bravo G, Sasaki K, Kadia TM, Khoury J, Wang SA, Haddad FG, Jacob J, Garris R, Ravandi F, Kantarjian HM. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. Lancet Haematol 10(6):e433-e444, 2023. e-Pub 2023. PMID: 37187201.
24. Haddad FG, Kantarjian HM, Bidikian A, Jabbour EJ, Short NJ, Ning J, Xiao L, Pemmaraju N, DiNardo CD, Kadia TM, Marx KR, Garcia-Manero G, Ravandi F, Sasaki K, Issa GC. Association between bariatric surgery and outcomes in chronic myeloid leukemia. Cancer 129(12):1866-1872, 2023. e-Pub 2023. PMID: 36882573.
25. Kantarjian H, Haddad FG, Jain N, Sasaki K, Short NJ, Loghavi S, Kanagal-Shamanna R, Jorgensen J, Khouri I, Kebriaei P, Alvarado Y, Kadia T, Paul S, Garcia-Manero G, Dabaja B, Yilmaz M, Jacob J, Garris R, O'Brien S, Ravandi F, Jabbour E. Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia. J Hematol Oncol 16(1):44, 2023. e-Pub 2023. PMID: 37131217.
26. Jabbour EJ, Sasaki K, Haddad FG, Issa GC, Garcia-Manero G, Kadia TM, Jain N, Yilmaz M, DiNardo CD, Patel KP, Kanagal-Shamanna R, Champlin R, Khouri IF, Dellasala S, Pierce SA, Kantarjian H. The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors. Am J Hematol 98(4):658-665, 2023. e-Pub 2023. PMID: 36683287.
27. Senapati J, Abuasab T, Haddad FG, Ravandi F, Kadia T, DiNardo C, Daver N, Pemmaraju N, Alvarado Y, Brandt MA, Kantarjian H, Borthakur G. Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G-CSF based regimens. Am J Hematol 98(3):E53-E56, 2023. e-Pub 2022. PMID: 36565294.
28. Kantarjian H, Short NJ, Jain N, Sasaki K, Huang X, Haddad FG, Khouri I, DiNardo CD, Pemmaraju N, Wierda W, Garcia-Manero G, Kebriaei P, Garris R, Loghavi S, Jorgensen J, Kwari M, O'Brien S, Ravandi F, Jabbour E. Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results. Am J Hematol 98(3):493-501, 2023. e-Pub 2023. PMID: 36600670.
29. Bataller A, Haddad FG, Issa GC, Sasaki K, Jabbour E, Borthakur G, Ferrajoli A, Short NJ. Sudden lymphoid blast crisis after tyrosine kinase inhibitor discontinuation in chronic phase chronic myeloid leukemia: cautionary tales for appropriate molecular monitoring. Leuk Lymphoma 64(3):1-4, 2023. e-Pub 2023. PMID: 36657414.
30. Jabbour E, Short NJ, Jain N, Haddad FG, Welch MA, Ravandi F, Kantarjian H. The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades. J Hematol Oncol 16(1):22, 2023. e-Pub 2023. PMID: 36927623.
31. Jabbour E, Short NJ, Jain N, Huang X, Montalban-Bravo G, Banerjee P, Rezvani K, Jiang X, Kim KH, Kanagal-Shamanna R, Khoury JD, Patel K, Kadia TM, Daver N, Chien K, Alvarado Y, Garcia-Manero G, Issa GC, Haddad FG, Kwari M, Thankachan J, Delumpa R, Macaron W, Garris R, Konopleva M, Ravandi F, Kantarjian H. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol 10(1):e24-e34, 2023. e-Pub 2022. PMID: 36402146.
32. Haddad FG, Sawyers J, Short NJ. Treatment de-escalation in Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia: the emerging role of chemotherapy-free regimens. Ther Adv Hematol 14:20406207231151294, 2023. e-Pub 2023. PMID: 36755897.
33. Jabbour E, Sasaki K, Haddad FG, Issa GC, Skinner J, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Garcia-Manero G, Takahashi K, Borthakur G, Pemmaraju N, Pierce S, Kantarjian H. Low-dose dasatinib 50 mg/day versus standard-dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis. Am J Hematol 97(11):1413-1418, 2022. e-Pub 2022. PMID: 36054032.
34. Lachowiez CA, Reville PK, Kantarjian H, Jabbour E, Borthakur G, Daver N, Issa G, Furudate K, Tanaka T, Pierce S, Tang G, Patel KP, Medeiros J, Abbas HA, Haddad F, Hammond D, Short NJ, Maiti A, Yilmaz M, Sasaki K, Takahashi K, Pemmaraju N, Konopleva M, Garcia-Manero G, Ravandi F, Kadia TM, Loghavi S, DiNardo CD. Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment. Am J Hematol 97(11):1443-1452, 2022. e-Pub 2022. PMID: 36054614.
35. Jabbour E, Haddad FG, Short NJ, Kantarjian H. Treatment of Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia-From Intensive Chemotherapy Combinations to Chemotherapy-Free Regimens: A Review. JAMA Oncol 8(9):1340-1348, 2022. PMID: 35834222.
36. Lachowiez CA, Reville PK, Kantarjian H, Jabbour E, Borthakur G, Daver N, Issa G, Furudate K, Tanaka T, Pierce S, Tang G, Patel KP, Medeiros J, Abbas HA, Haddad FG, Hammond D, Short NJ, Maiti A, Yilmaz M, Sasaki K, Takahashi K, Pemmaraju N, Konopleva M, Garcia-Manero G, Ravandi F, Kadia TM, Loghavi S, DiNardo CD.. Contemporary outcomes in IDH-mutated AML: The impact of co-occurring NPM1 mutations and venetoclax-based treatment. Am J Hematol, 2022. e-Pub 2022.
37. Haddad FG, Sasaki K, Issa GC, Garcia-Manero G, Ravandi F, Kadia T, Cortes J, Konopleva M, Pemmaraju N, Alvarado Y, Yilmaz M, Borthakur G, DiNardo C, Jain N, Daver N, Short NJ, Jabbour E, Kantarjian H. Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. Am J Hematol 97(7):856-864, 2022. e-Pub 2022. PMID: 35357036.
38. Hbaddad F|, Kantarjian H, Issa GC, Jabbour E, Sasaki K. Intracranial hypertension associated with BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia. Leuk Lymphoma 63(7):1714-1717, 2022. e-Pub 2022. PMID: 35361036.
39. Saadé MC, Gh Haddad F, Sukkarieh G, Mechleb N, Waked N. The role of funduscopy in severe thrombocytopenia: A prospective study. Transfus Clin Biol 29(2):138-140, 2022. e-Pub 2021. PMID: 34923149.
40. Elias Jabbour, MD; Haddad FG; Nicholas J. Short, MD; Hagop Kantarjian, MD. Treatment of Adults with Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia—From Intensive Chemotherapy Combinations to Chemotherapy-Free Regimens. JAMA Oncology, 2022. e-Pub 2022.
41. Richard-Carpentier G, Kantarjian HM, Tang G, Yin CC, Khoury JD, Issa GC, Haddad F, Jain N, Ravandi F, Short NJ, DiNardo CD, Takahashi K, Konopleva MY, Daver NG, Kadia T, Garcia-Manero G, Garris R, O'Brien S, Jabbour E. Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience. Blood Adv 5(23):5415-5419, 2021. PMID: 34525185.
42. Issa GC, Zarka J, Sasaki K, Qiao W, Pak D, Ning J, Short NJ, Haddad F, Tang Z, Patel KP, Cuglievan B, Daver N, DiNardo CD, Jabbour E, Kadia T, Borthakur G, Garcia-Manero G, Konopleva M, Andreeff M, Kantarjian HM, Ravandi F. Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. Blood Cancer J 11(9):162, 2021. e-Pub 2021. PMID: 34588432.
43. Abi Karam M, Kourie HR, Jalkh N, Mehawej C, Kesrouani C, Haddad FG, Feghaly I, Chouery E, Tomb R. Molecular profiling of basal cell carcinomas in young patients. BMC Med Genomics 14(1):187, 2021. e-Pub 2021. PMID: 34284772.
44. Bou Khalil R, Kassab A, Costa G, Haddad FG, Richa S, Kattan J.. Increased psychomotor retardation and tension as short-term neuropsychiatric adverse events of immune checkpoint inhibitors: A prospective cohort study. Journal of Cancer Research and Therapeutics, 2021. e-Pub 2021.
45. Eid R, Hage S, Antonios I, Moussa R, Khoury M, Haddad FG, Kourie HR, Kesrouani C, Ghorra C, Abadjian G, Kattan J. Epidemiologic and histologic characteristics of CNS lesions: a 20-year experience of a tertiary center in Lebanon. CNS Oncol 9(2):CNS55, 2020. e-Pub 2020. PMID: 32603607.
46. Richa S, Herdane M, Dwaf A, Bou Khalil R, Haddad F, El Khoury R, Zarzour M, Kassab A, Dagher R, Brunet A, El-Hage W. Trauma exposure and PTSD prevalence among Yazidi, Christian and Muslim asylum seekers and refugees displaced to Iraqi Kurdistan. PLoS One 15(6):e0233681, 2020. e-Pub 2020. PMID: 32579560.
47. Costa J, Haddad FG, Costa G, Harb A, Eid R, Kourie HR, Helou J.. Seizures in cancer patients: a vast spectrum of etiologies. Future Neurology, 2019. e-Pub 2019.
48. El Karak F, Gh Haddad F, Eid R, Al Ghor M, El Rassy E, Ahmadieh N, Choullamy T, Halim NA, Tfayli A, Farhat F, Kattan J, Nasr F, Ghosn M, Assi HI. Lung cancer and immunotherapy: a real-life experience from second line and beyond. Future Oncol 15(26):3025-3032, 2019. e-Pub 2019. PMID: 31424958.
49. Assi T, Bakouny Z, Labaki C, El Rassy E, Khazzaka A, Jabbour R, Haddad FG, Tohme A, El Karak F, Ghosn M, Kattan J. Causes of death in older patients with cancer: Experience of a tertiary care center in Lebanon. J Geriatr Oncol 10(2):365-367, 2019. e-Pub 2018. PMID: 30391115.
50. Alkassis M, Haddad FG, Gharios J, Noun R, Chakhtoura G. Quality of Life before and after Sleeve Gastrectomy in Lebanese Population. J Obes 2019:1952538, 2019. e-Pub 2019. PMID: 31467704.
51. Rassy EE, Bakouny Z, Aoun F, Haddad FG, Sleilaty G, Assi T, Kattan J. A network meta-analysis of the PD(L)-1 inhibitors in the salvage treatment of urothelial bladder cancer. Immunotherapy 10(8):657-663, 2018. e-Pub 2018. PMID: 29562804.
52. El Rassy E, Ghosn M, Farhat F, Bakouny Z, Assi T, Chahine G, Nasr F, Haddad FG, El Karak F, Kattan J. Toxicities Associated with Docetaxel-Based Regimens in the Adjuvant Treatment of Early-Stage Breast Cancer: A Multicenter Prospective Real-Life Experience. Breast Care (Basel) 13(2):121-125, 2018. e-Pub 2018. PMID: 29887789.
53. Kourie HR, Bakouny Z, Eid R, Haddad FG, Kattan J. The merit of tyrosine kinase inhibitors in the adjuvant setting of high-risk renal cell carcinoma: a meta-analysis. Future Oncol 14(9):829-835, 2018. e-Pub 2018. PMID: 29589470.
54. Haddad FG, Kattan J, Kourie HR, El Rassy E, Assi T, Adib SM. Geriatric cancer trends in the Middle-East: Findings from Lebanese cancer projections until 2025. J Geriatr Oncol 9(2):120-123, 2018. e-Pub 2017. PMID: 28877856.
55. Chelala E, Arej N, Antoun J, Kourie HR, Zaarour K, Haddad FG, Farhat F, El Karak F, Kattan J. Central Macular Thickness Monitoring after a Taxane-Based Therapy in Visually Asymptomatic Patients. Chemotherapy 62(3):199-204, 2017. e-Pub 2017. PMID: 28351058.
56. El Karak F, El Rassy E, Naderi S, Al Ghor M, Khoury J, Haddad FG, Ghosn M, Farhat F, Kattan J, Ghorra C.. Successful ALK Targeting in Small-Cell Lung Cancer. PAJO, 2017. e-Pub 2017.
57. Haddad FG, Kourie HR, Adib SM. Trends in mammography utilization for breast cancer screening in a Middle-Eastern country: Lebanon 2005-2013. Cancer Epidemiol 39(6):819-24, 2015. e-Pub 2015. PMID: 26651440.
58. Naderi S, Ghorra C, Haddad F, Kourie HR, Rassy M, El Karak F, Ghosn M, Abadjian G, Kattan J. EGFR mutation status in Middle Eastern patients with non-squamous non-small cell lung carcinoma: A single institution experience. Cancer Epidemiol 39(6):1099-102, 2015. e-Pub 2015. PMID: 26362141.

Invited Articles

1. Haddad FG, Kantarjian H. Navigating the Management of Chronic Phase CML in the Era of Generic BCR::ABL1 Tyrosine Kinase Inhibitors. JNCCN 22(1), 2024.
2. Haddad FG, Short NJ. Evidence-Based Minireview: What is the optimal tyrosine kinase inhibitor for adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia?. Hematology Am Soc Hematol Educ Program 1(1):213-217, 2022. e-Pub 2022. PMID: 36485089.
3. Haddad FG, Kantarjian H, Jabbour E. EXABS-133-ALL Approach to Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 22(Suppl 2):S39-S41, 2022. PMID: 36164110.
4. Haddad FG, Issa GC, Jabbour E, Yilmaz M. Ponatinib for the treatment of adult patients with resistant or intolerant Chronic-Phase Chronic Myeloid Leukemia. Expert Opin Pharmacother 23(7):751-758, 2022. e-Pub 2022. PMID: 35412404.
5. Haddad F, Zeidan AM, Daver N. Checkpoint Inhibitors and Other Immune-Based Therapies in Acute Myeloid Leukemia. Cancer J 28(1):43-50, 2022. e-Pub 2022. PMID: 35072373.
6. Haddad F, Zeidan A, Daver N. Checkpoint Inhibitors and Other Immune-Based Therapies in Acute Myeloid Leukemia. The Cancer Journal 28(1), 2022. e-Pub 2022.
7. Haddad F, Daver N. Targeting CD47/SIRPα in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Preclinical and Clinical Developments of Magrolimab. J Immunother Precis Oncol 4(2):67-71, 2021. e-Pub 2021. PMID: 35663535.

Manuals, Teaching Aids, Other Teaching Publications

1. Haddad FG. Hyperleukocytosis and Leukostasis in Hematologic Malignancy. Elsevier Clinical Key, 2024.

Other Articles

1. Jammal N, Kantarjian HM, Haddad F, Jabbour EJ Management of Acute Lymphoblastic Leukemia in Older Adults. Clin Adv Hematol Oncol 20(3):161-168, 2022. PMID: 36607346.
2. Jabbour E, Haddad F, Short N, Kantarjian H Treatment of Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Review of Evidence from Intensive Chemotherapy Combinations to Chemotherapy-Free Regimens. Accepted for publication in JAMA Oncology, 2022.
3. Haddad FG, Chebly A, El Sett A, Kourie HR, Farra C An unusual case of chronic lymphocytic leukemia with trisomy 12 and t(14;18) and a favorable response to ibrutinib. Leuk Res Rep 15:100245, 2021. PMID: 34040960.
4. Haddad FG, Daver N. Targeting CD47/SIRPa in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Preclinical and Clinical Developments of Magrolimab,. Journal of Immunotherapy and Precision Oncology, 2021.
5. Elkaddoum R, Haddad FG, Eid R, Kourie HR. In reply: incorporating teleoncology practices in the undergraduate medical curriculum. Future Oncol, 2021.
6. Haddad FG, Kattan C, Kattan J Should immune checkpoint inhibitors be contraindicated in lung cancer patients with latent tuberculosis?. Immunotherapy 12(11):759-762, 2020. PMID: 32517560.
7. Haddad G, Saadé MC, Eid R, Haddad FG, Kourie HR PARP inhibitors: a tsunami of indications in different malignancies. Pharmacogenomics 21(3):221-230, 2020. PMID: 31967513.
8. Chebly A, Haddad FG, Bassil J, Yammine T, Korban R, Semaan W, El Karak F, Kourie HR, Farra C A rare case of acute myeloid leukemia with t(12;19)(q13;q13). Leuk Res Rep 14:100216, 2020. PMID: 32637310.
9. Moujaess E, Haddad FG, Eid R, Kourie HR The emerging use of immune checkpoint blockade in the adjuvant setting for solid tumors: a review. Immunotherapy 11(16):1409-1422, 2019. PMID: 31621445.
10. Hajjar AH, Eid R, Haddad FG, Kourie HR FOLFIRINOX: a new standard of care in the adjuvant setting of resectable pancreatic adenocarcinomas. Future Oncol 15(17):1947-1950, 2019. PMID: 31185748.
11. Mehanna J, Haddad FG, Eid R, Lambertini M, Kourie HR Triple-negative breast cancer: current perspective on the evolving therapeutic landscape. Int J Womens Health 11:431-437, 2019. PMID: 31447592.
12. Kattan J, Haddad FG, Menassa-Moussa L, Kesrouani C, Daccache S, Haddad FG, Atallah D Peritoneal Tuberculosis: A Forsaken Yet Misleading Diagnosis. Case Rep Oncol Med 2019:5357049, 2019. PMID: 31781444.
13. Kourie HR, Bakouny Z, Haddad FG, Eid R, Kattan J Adjuvant tyrosine kinase inhibitors for renal cell carcinoma? No, thank you (at least for the present) reply. Future Oncol 14(22):2225-2227, 2018. PMID: 30064260.
14. Hobeika C, Rached G, Eid R, Haddad F, Chucri S, Kourie HR, Kattan J ALK-rearranged adenocarcinoma transformed to small-cell lung cancer: a new entity with specific prognosis and treatment?. Per Med 15(2):111-115, 2018. PMID: 29714122.
15. Saleh K, Eid R, Haddad FG, Khalife-Saleh N, Kourie HR New developments in the management of head and neck cancer - impact of pembrolizumab. Ther Clin Risk Manag 14:295-303, 2018. PMID: 29497306.
16. Haddad FGH, Yared F, Alam A, Salem C, Kattan J Dual Synchronous Metastases to Pancreas and the Breast from a Small Cell Lung Cancer: A Case Report. Case Reports and Literature Review 2(2), 2018.
17. Mehanna J, Haddad FG, Eid R, Lambertini M, Kourie HR "What is the role of HER2-specific antibody immunity in patients with HER2-positive early breast cancer receiving chemotherapy plus trastuzumab?". Translational Cancer Research 7.6, 2018.
18. El Karak F, El Rassy E, Naderi S, Al Ghor M, Khoury J, Haddad FGH, Ghosn M, Farhat F, Kattan J, Ghorra C Successful ALK Targeting in Small-Cell Lung Cancer. PAJO 10(3), 2017.
19. Ghosn M, Kourie HR, El Rassy E, Haddad FG, Hanna C, El Karak F, Nasr D Where does chemotherapy stands in the treatment of ampullary carcinoma? A review of literature. World J Gastrointest Oncol 8(10):745-750, 2016. PMID: 27795814.
20. Rassy EE, Tabchi S, Haddad FG, Chebib R, Assi T, Kourie HR, Nasr F Acquired factor inhibitor in a patient with monoclonal gammopathy of undetermined significance responding to rituximab. Blood Coagul Fibrinolysis 27(7):822-824, 2016. PMID: 26626040.

Editorials

1. Catueno S, Haddad FG, Cuglievan B. The efficacy of homoharringtonine in pediatric acute myeloid leukemia: findings from the Chinese Children’s Leukemia Group-AML 2015 Study. Transl Pediatr 13(2):376-379, 2024. PMID: 38455741.
2. Haddad FG, Jabbour E. Long-Term Outcomes of Dasatinib–Blinatumomab in Adults With Ph+ Acute Lymphoblastic Leukemia. Practice Update, 2024.
3. Zouein J, Haddad FG, Eid R, Kourie HR. The combination of immune checkpoint inhibitors and chemotherapy in advanced non-small-cell lung cancer: the rational choice. Immunotherapy 14(2):155-167, 2022. PMID: 34865502.
4. Elkaddoum R, Haddad F, Eid R, Kourie HR. In reply: incorporating teleoncology practices in the undergraduate medical curriculum. Future Oncol 17(1), 2021.
5. Kourie HR, Eid R, Haddad F, Ghosn M, Sarkis DK. The future of cancer research after COVID-19 pandemic: recession?. Future Oncol 16(21):1493-1495, 2020. PMID: 32469283.
6. Haddad FG, Karam E, Moujaess E, Kourie HR. Poly-(ADP-ribose) polymerase inhibitors: paradigm shift in the first-line treatment of newly diagnosed advanced ovarian cancer. Pharmacogenomics 21(10):721-727, 2020. PMID: 32597301.
7. Elkaddoum R, Haddad FG, Eid R, Kourie HR. Telemedicine for cancer patients during COVID-19 pandemic: between threats and opportunities. Future Oncol 16(18), 2020. PMID: 32356460.
8. Akiki M, Haddad FG, Kourie HR, Khaddage A, Smayra VT. PD-L1: an unavoidable biomarker in advanced triple-negative breast cancer. Biomark Med 13(18):1539-1541, 2019. PMID: 31631684.
9. Semaan A, Haddad FG, Eid R, Kourie HR, Nemr E. Immunotherapy: last bullet in platinum refractory germ cell testicular cancer. Future Oncol 15(5):533-541, 2019. PMID: 30624089.
10. Haddad FG, Eid R, Kourie HR, Barouky E, Ghosn M. Prognostic and predictive biomarkers in nonmetastatic colorectal cancers. Future Oncol 14(21):2097-2102, 2018. PMID: 30101612.
11. Eid R, Nemr E, Haddad FG, Kourie HR, Kattan J. Do checkpoint inhibitors provide new hope for management of metastatic penile carcinoma?. Future Oncol 14(8):677-680, 2018. PMID: 29521122.
12. Eid R, Haddad FG, Kourie HR, Kattan J. Electronic patient-reported outcomes: a revolutionary strategy in cancer care. Future Oncol 13(27):2397-2399, 2017. PMID: 29121784.
13. Haddad FG, Kourie HR, Kattan J. Targeting EGFR mutation in non-small-cell lung cancer: challenges and future perspectives. Future Oncol 13(3):201-204, 2017. PMID: 27624407.

Abstracts

1. Gener-Ricos G, Borthakur G, Sasaki K, Tang G, Montalban-Bravo G, Jabbour E , Ohanian M, Yilmaz M, Haddad FG, Chien KS, Ishizawa J, Short NJ, Maiti A, Swaminathan M, Garcia-Manero G, Daver N, DiNardo CD, Ravandi F, Kadia TM. Cladribine, High-Dose AraC, Plus Gemtuzumab Ozogamicin (CLAG-GO) As Frontline Intensive Therapy for Fit Patients with Core-Binding Factor Acute Myeloid Leukemia: Preliminary Results. Blood 142(Supp 1):2903, 2023.
2. Senapati J, Jabbour E, Short NJ, Tang G, Haddad FG, Jain N, Issa GC, Kadia TM, Daver N, Ferrajoli A, Kwari M, Garcia-Manero G, Montalban-Bravo G, Nasnas PE, Pemmaraju N, Garris R, Ravandi F, Kantarjian HM. Impact of High-Risk Cytogenetics (HR-CTG) on the Outcome of Newly Diagnosed Adult Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL) Treated with Frontline Blinatumomab (Blina) and/or Inotuzumab Ozogamicin (Ino) Containing Hypercvad (HCVAD) Therapy. Blood 142(Supp 1):1500, 2023.
3. Jamison T, Kantarjian HM, Paul S, Cuglievan B, McCall D, Jain N, <b>Haddad FG</b>, Marx KR, Rausch CR, Savoy JM, Nasr L, Nasnas C, Zoghbi M, Garris R, Ravandi F, Konopleva MY, Jabbour E, Short NJ. “Dose-Dense” Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves High Rates of Rapid MRD-Negativity in Patients with Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: A Retrospective Analysis. Blood 142(Supp 1):1508, 2023.
4. Haddad F, Jabbour E, Sasaki K, Nasr L, Huang X, Issa GC, Ravandi F, Garcia-Manero G, Kadia TM, Daver N, Valero YA, Nasnas C, Ohanian M, Short NJ, Masarova L, Zoghbi M, Nasnas PE, Montalban-Bravo G, Skinner J, Pierce S, Andreeff M, Kantarjian HM. Phase 2 Study of Dasatinib with and without Venetoclax in Patients with Early Chronic Phase Chronic Myeloid Leukemia (ECP-CML). Blood 142(Supp 1):870, 2023.
5. Nguyen D, Kantarjian HM, Short NJ, Jain N, Haddad FG, Yilmaz M, Ferrajoli A, Kadia TM, Valero YA, Maiti A, Nasnas C, Nasr L, Garris R, Konopleva MY, Ravandi F, Jabbour E. Updated Results from a Phase II Study of Hyper-CVAD, with or without Inotuzumab Ozogamicin, and Sequential Blinatumomab in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia. Blood 142(Supp 1):4245, 2023.
6. Burger JA, Kim E, Sivina M, Mathew T, Danielle E. Hammond DE, Haddad FG, Ferrajoli A, Wierda WG. Time-Limited Therapy with Zanubrutinib Plus Rituximab in Treatment-Naïve Chronic Lymphocytic Leukemia: Early Results of an Ongoing Phase 2 Trial. Blood 142(Supp 1):6524, 2023.
7. Rami Bou Khalil RB, Haddad FG, Cordahi CC, Fiani D, Moukarzel JM, Chamoun Y, Kourie HR, Richa S, Kattan J. Cognitive functions of patients treated with chemotherapy: A comparative studyLes fonctions cognitives des sujets sous chimiothérapie : étude comparative. Science Direct, 2023.
8. Short NJ, Jabbour E, Jain N, Haddad FG, Macaron W, Yilmaz M, Ferrajoli A, Kadia TM, Alvarado Valero Y, Maiti A, Nasr LF, Zoghbi M, Nasnas CC, Garris R, Zhao M, Konopleva M, Ravandi F, Kantarjian HM. A phase II study of hyper-CVAD with blinatumomab (blina) and inotuzumab ozogamicin (INO) for newly diagnosed Philadelphia chromosome (Ph)–negative B-cell acute lymphoblastic leukemia (ALL). Journal of Clinical Oncology 41(Supp. 16):19017-19017, 2023.
9. Short NJ, Jabbour E, Jain N, Macaron W, Huang X, Montalban-Bravo G, Kadia TM, Daver NG, Haddad F, Zoghbi M, Nasnas CC, Nasr LF, Mayor E, Deen W, Thankachan J, Loiselle C, Garris R, Konopleva M, Ravandi F, Kantarjian HM. A phase II trial of ponatinib and blinatumomab in adults with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL). Journal of Clinical Oncology 41(Supp. 16):19013-19013, 2023. e-Pub 2023.
10. Bidikian A, Haddad F, Sasaki K, Issa G, Kadia T, Jain N, Alvarado Y, Short N, Yilmaz M, Masarova L, Jabbour E, Kantarjian H. Characteristics and Outcomes of Patients with Chronic Myeloid Leukemia and T315i Mutation after Failure of Prior Therapies. EHA Library, 2023.
11. Haddad F, Jabbour E, Zoghbi M, Short N, Senapati J, Macaron W, Nasnas C, Nasr L, Pemmaraju N, Jain N, Wierda WG, Borthakur G, Montalban-Bravo G, Ravandi F, Garcia-Manero G, Kadia T, Chien K, Thankachan J, Garris R, Kantarjian H. A Phase II Trial of Mini-Hyper-CVD with Venetoclax for Patients with Relapsed/Refractory (R/R) Philadelphia Chromosome (Ph)-Negative Acute Lymphoblastic Leukemia (All). EHA Library, 2023.
12. Jen WJ, Jabbour E, Haddad F, Nasr L, Short N, Zoghbi M, Nasnas C, Issa G, Yilmaz M, Daver N, Pemmaraju N, Masarova L, Ravandi F, Jain N, Deen W, Loiselle C, Waller L, Banks G, Garris R, Kantarjian H. A Phase II Study of Low-Intensity Chemotherapy (Mini-Hyper-CVD) and Ponatinib Followed By Blinatumomab and Ponatinib in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. EHA Library 142(Supp 1):2868, 2023.
13. Haddad F, Jabbour E, Nasnas C, Short N, Nasr L, Macaron W, Zoghbi M, Ravandi F, Jain N, Kadia T, Daver N, Borthakur G, DiNardo C, Jacob J, Roy E, Loiselle C, Milton A, Rivera J, Garris R, Kantarjian H. Updates from A Phase II Trial of Mini-Hyper-CVD-Inotuzumab with or without Blinatumomab in Older Patients with Newly Diagnosed Philadelphia Chromosome (Ph)-Negative Acute Lymphoblastic Leukemia. EHA Library, 2023.
14. Haddad F, Jabbour E, Zoghbi M, Short N, Nasnas C, Nasr L, Macaron W, Jain N, Huang X, Montalban-Bravo G, Kadia T, Daver N, Chien K, Alvarado Y, Garcia-Manero G, Issa G, Kwari M, Delumpa R, Mayor E, Deen W, Thankachan J, Loiselle C, Rivera J, Milton L, Waller L, Banks G, Garris R, Ravandi F, Kantarjian H. Ponatinib and Blinatumomab in Relapsed/Refractory Philadelphia-Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia in Lymphoid Blast Phase: Subgroup Analysis from A Phase II Trial. EHA Library, 2023.
15. Nasr LF, Jabbour E, Haddad FG, Short NJ, Macaron W, Nasnas CC, Zoghbi M, Issa GC, Yilmaz M, Daver NG, Pemmaraju N, Masarova L, Ravandi F, Jain N, Deen W, Loiselle C, Waller L, Banks G, Garris R, Kantarjian HM. Low-intensity chemotherapy (mini-HCVD) and ponatinib followed by blinatumomab (blina) and ponatinib for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL): A phase II study. Journal of Clinical Oncology 41(Supp. 16):19028-19028, 2023.
16. Nasnas CC, Jabbour E, Haddad F, Short NJ, Nasr LF, Macaron W, Zoghbi M, Ravandi F, Jain N, Kadia TM, Daver NG, Borthakur G, Dinardo CD, Jacob J, Roy E, Loiselle C, Milton A, Rivera J, Garris R, Kantarjian HM. Mini-hyper-CVD plus inotuzumab ozogamicin (InO), with or without blinatumomab (Blina), in older patients with newly diagnosed Philadelphia chromosome (Ph)-negative B-cell acute lymphoblastic leukemia (ALL): Updates from a phase II trial. Journal of Clinical Oncology 41(Supp. 16):19025-19025, 2023.
17. Nasnas CC, Jabbour E, Haddad F, Short NJ, Macaron W, Zoghbi M, Nasr LF, Jain N, Almanza E, Sasaki K, Ravandi F, Kebriaei P, Huang X, Garcia-Manero G, Kadia TM, Wang SA, Jacob J, Garris R, O'Brien SM, Kantarjian HM. Phase II trial of mini-hyper-CVD-inotuzumab (InO) followed by blinatumomab (blina) consolidation in patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL. Journal of Clinical Oncology 41(Supp. 16):e19037-e19037, 2023.
18. Zoghbi M, Jabbour E, Haddad F, Short NJ, Senapati J, Macaron W, Nasnas CC, Nasr LF, Pemmaraju N, Jain N, Wierda WG, Borthakur G, Montalban Bravo G, Ravandi F, Garcia-Manero G, Kadia TM, Chien KS, Thankachan J, Garris R, Kantarjian HM. Mini-hyper-CVD with venetoclax (Ven) for patients with relapsed/refractory (R/R) Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL): A phase II study. Journal of Clinical Oncology 41(Supp. 16):e19039, 2023.
19. Zoghbi M, Jabbour E, Haddad F, Short NJ, Nasnas CC, Macaron W, Nasr LF, Jain N, Montalban-Bravo G, Kadia TM, Daver NG, Chien KS, Alvarado Valero Y, Issa GC, Mayor E, Deen W, Thankachan J, Garris R, Ravandi F, Kantarjian HM. Subgroup analysis from a phase II trial of ponatinib and blinatumomab in relapsed/refractory (R/R) Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia in lymphoid blast phase. Journal of Clinical Oncology 41(Supp. 16):e19038-e19038, 2023.
20. Bazinet A, Kadia T, Short NJ, Borthakur G, Wang SA, Wang W, Loghavi S, Jorgensen J, Patel K, DiNardo C, Naval Daver N, Yesid Alvarado Y, Haddad FG, Pierce S, Gonzalez GN, Maiti A, Sasaki K, Yilmaz M, Thompson P, Wierda W, Garcia-Manero G, Andreeff M, Jabbour, E, Konopleva M, Huang X, Kantarjian H, Ravandi F. Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity. Blood Advances 7(13):3284–3296, 2023. e-Pub 2023.
21. Jabbour, E, Haddad FG, Short NJ, Senapati J, Jain N, Sasaki K, Jorgensen JL, Wang SA, Alvarado Y, Wang X, DiNardo CD, Masarova L, Kadia TM, Garris R, Ravandi F, Kantarjian H,. Phase II Study of Inotuzumab Ozogamicin for Measurable Residual Disease in Acute Lymphoblastic Leukemia in Remission. Blood, 2023.
22. Haddad FG, Jabbour E, Short NJ, Jain N, Huang X, Montalban-Bravo G, Kadia TM, Daver N, Nasnas C, Mayor E, Nasnas PE, Deen W, Zoghbi M, Thankachan J, Loiselle C, Garris R, Ravandi F, Kantarjian HM. Chemotherapy-Free Combination of Blinatumomab and Ponatinib in Adults with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Updates from a Phase II Trial. Blood 142(Supp 1):2827, 2023.
23. Jen WJ, Jabbour E, Haddad F, Short N, Jain N, Kadia TM, Daver N, Borthakur G, Nasr L, DiNardo CD, Zoghbi M, Jacob J, Roy E, Loiselle C Milton A, Rivera J, Garris R, Ravandi F, Kantarjian HM. Phase 2 Trial of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. Blood 142(Supp 1):2878, 2023.
24. Haddad F, Kantarjian H, Jabbour E, Short N, Pemmaraju N, Marx K, Ravandi F, Sasaki K, Issa G. Association Between Bariatric Surgery and Outcomes in Patients with Chronic Myeloid Leukemia Treated with Oral Tyrosine Kinase Inhibitors. Blood 138(Supp. 1):2560, 2022.
25. Haddad F, Kantarjian H, Short N, Konopleva M, Jain N, Ravandi F, Daver N, Alvarado Y, Takahashi K, Garcia-Manero G, Velasquez M, Garris R, Jabbour E. A Phase II Study of Blinatumomab for the Treatment of Measurable Residual Disease-Positive B-cell Acute Lymphoblastic Leukemia. Blood 138(Supp. 1):4398, 2022.
26. Mohamed SF, Abuasbab T, Chien K, Montalban-Bravo G, Darbaniyan F, Pierce S, Soltysiak K, Haddad F, McCall D, Cuglievan B, Jabbour E, Daver N, Kadia T, Pemmaraju N, Kantarjian H, Garcia-Manero G. Characteristics And Outcomes Of Adolescent And Young Adult (AYA) Patients With Myelodysplastic Syndrome (MDS) And Chronic Myelomonocytic Leukemia (CMML): A Single-Center Retrospective Analysis. Blood 140(Supp. 1):11661-11662, 2022.
27. Aldapt M, Haddad F, Abuasab T, Soliman DS, Abbas F, Mosalem O, Ahmed A, Saeed S, Abdulla MA, Mohamed SF. Extramedullary Hematopoiesis (EMH) and Myelodysplastic Syndrome (MDS): Review. Blood 140(Supp 1):12331-12332, 2022.
28. Ahmed A, Saeed S, Soliman DS, Haddad F, Abuasab T, Abbas F, Abdulla MA, Mohamed SF. Hematoma or Bleeding As Initial Presentation of Chronic Myeloid Leukemia (CML): Review. Blood 140(Supp. 1):12231-12232, 2022.
29. Aldapt MB, Soliman DS, Haddad F, Abuasab T, Abbas F, Mosalem O, Ahmed A, Saeed S, Shwaylia H, Abdulla M, Mohamed SF. Myeloid Sarcoma in Myelodysplastic Syndrome : Review. Blood 140(Supp. 1):12333-123324, 2022.
30. Bataller A, Sasaki K, Jabbour E, Issa GC, Haddad F, Skinner J, Dellasala SE, Garcia-Manero G, Pierce SA, Kantarjian H. Prognostic Model of Transformation to Blast Phase in Patients with Chronic Myeloid Leukemia. Blood 140(Supp. 1):3895-3895, 2022.
31. Mohamed SF, Mulikandathil Y, Soliman DS, Abbas F, Alshurafa A, Afana M, Ellahie AY, Mudawi DS, Omri HE, Gameil A, Abuasab T, Haddad F, Singh K, Kassem N, Cherif H. Clinicopathologic Characteristics and Outcome of Acute Myeloid Leukemia with (AML) with Core Binding Factor (CBF) Rearrangements: A Retrospective Study. Blood 140(Supp.1):11651-11652, 2022.
32. Mohamed SF, Alshurafa A, Soliman DS, Omri HE, Mudawi DS, Yassin MA, Afana M, Elsabah H, Ellahie AY, Kassem N, Abuasab T, Haddad F, Kohla S, Amer A, Singh K, Cherif H. A Comparative Study between Acute Myeloid Leukemia in Adolescent and Young Adults (AYA) Versus Non-AYA Patients: Single Center Experience. Blood 140(Supp. 1):11646-11648, 2022.
33. Gener-Ricos G, Haddad F, Sasaki K, Issa GC, Skinner J, Takahashi K, Masarova L, Burger JA, Borthakur G, Bose P, Garcia-Manero G, Jabbour E, Kantarjian H. Long-Term Follow-up of Low-Dose Dasatinib (50mg Daily) As Frontline Therapy in Newly Diagnosed Chronic Myeloid Leukemia. Blood 140(Supp. 1):1493-1494, 2022.
34. Abuasab T, Haddad F, Mohamed SF, Jorgensen JL, Wang SA, Thompson PA, Kadia TM, Alvarado Y, Pierce SA, Keating MJ, McCue D, Kantarjian H, Ravandi F. Utility of Flow Cytometry in Monitoring of Measurable Residual Disease in Patients with Hairy Cell Leukemia. Blood 140(Supp. 1):9385-9386, 2022.
35. Haddad F, Sasaki K, Issa GC, Kim K, Skinner J, Dellasala SE, Alvarado Y, Ferrajoli A, Kadia TM, Yilmaz M, Pemmaraju N, Garcia-Manero G, Pierce SA, Jabbour E, Kantarjian H. More Than Ten Years Follow-up of Frontline Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Myeloid Leukemia. Blood 140(Supp, 1):3897-3899, 2022.
36. Gener-Ricos G, Sasaki K, Loghavi S, Maiti A, Short N, Haddad F, Daver N, Borthakur G, Ravandi F, Kantarjian H, Patel KP, Andreeff M, DiNardo CD. A Descriptive Analysis of TP53 Y220C Mutations in Patients with Hematologic Malignancies. Blood 140(Supp.1):11830-11832, 2022.
37. Senapati J, Short N, Jain N, Ravandi F, Bathala TK, Bidikian A, Haddad F, Nasnas P, Daver N, Kadia TM, Garris R, Kwari M, Kantarjian H, Jabbour E. Baseline Liver Elastography Does Not Predict Risks of Hepato-Toxicity to Reduced Dose Inotuzumab Therapy Combined with Minihcvd in B-Cell Acute Lymphoblastic Leukemia. Blood 140(Supp. 1):3182-3184, 2022.
38. Bidikian A, Kantarjian H, Issa GC, Ravandi F, Garcia-Manero G, Borthakur G, Kadia TM, Daver N, Jain N, Pemmaraju N, DiNardo CD, Haddad F, Pierce SA, Jabbour E, Sasaki K. Outcomes of Chronic Myeloid Leukemia with No Major Molecular Response within 2 Years of Tyrosine Kinase Inhibitor Therapy. Blood 140(Supp. 1):9626-9628, 2022.
39. Jabbour E, Sasaki K, Issa GC, Haddad F, Garcia-Manero G, Kadia TM, Wierda WG, Yilmaz M, DiNardo CD, Skinner J, Pemmaraju N, Dellasala SE, Pierce SA, Cortes JE, Kantarjian H. Outcome of Third-Line Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in Chronic Phase: A Propensity Score Analysis. Blood 140(Supp. 1):809-811, 2022.
40. Short N, Kantarjian H, Jain N, Huang X, Montalban-Bravo G, Kadia TM, Daver N, Chien KS, Alvarado Y, Garcia-Manero G, Issa GC, Macaron W, Haddad F, Kwari M, Delumpa R, Mayor E, Deen W, Thankachan J, Loiselle C, Rivera J, Milton A, Waller L, Banks B, Garris R, Konopleva M, Ravandi F, Jabbour E. Ponatinib and Blinatumomab for Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Subgroup Analysis from a Phase II Study. Blood 140(Supp. 1):513-515, 2022.
41. Haddad F, Medawar G, Kanagal-Shamanna R, Alvarez H, Loghavi S, Daver N, Pierce SA, Jabbour E, Kadia TM, Short N, DiNardo CD, Borthakur G, Abbas HA, Pemmaraju N, Garcia-Manero G, Ravandi F, Kantarjian H, Yilmaz M. Evaluation of Emergent FLT3 Mutations (FLT3m) at Relapse in Patients (Pts) with Wild-Type FLT3 Acute Myeloid Leukemia (AML). Blood 140(Supp. 1):396-3198, 2022.
42. Bazinet A, Kadia TM, Short N, Borthakur G, Wang SA, Loghavi S, Jorgensen JL, Patel KP, DiNardo CD, Daver N, Alvarado Y, Haddad F, Pierce SA, González GMN, Maiti A, Andreeff M, Jabbour E, Konopleva M, Huang X, Kantarjian H, Ravandi F. Achievement of Measurable Residual Disease (MRD) Negativity Supersedes Treatment Intensity in Predicting the Outcome of Patients with Acute Myeloid Leukemia. Blood 140(Supp. 1):2267-2269, 2022.
43. Macaron W, Kantarjian H, Short N, Jain N, Huang X, Montalban-Bravo G, Kadia TM, Daver N, Chien KS, Alvarado Y, Garcia-Manero G, Issa GC, Haddad F, Kwari M, Delumpa R, Mayor E, Deen W, Thankachan J, Loiselle C, Rivera J, Milton A, Waller L, Banks G, Garris R, Konopleva M, Ravandi F, Jabbour E. Ponatinib and Blinatumomab for Patients with Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia in Lymphoid Blast Phase: A Subgroup Analysis from a Phase II Study. Blood 140(Supp. 1):8973-8975, 2022.
44. Haddad F, Jabbour E, Short N, Jain N, Huante EA, Sasaki K, Nasnas P, Ravandi F, Kebriaei P, Huang X, Konopleva M, Garcia-Manero G, Champlin RE, Kadia TM, Takahashi K, Daver N, Khoury JD, Jorgensen JL, Wang SA, Jacob J, Garris R, Kantarjian H. Improved Outcomes with Low-Dose Inotuzumab and Mini-Hyper-CVD Followed By Blinatumomab Consolidation in Relapsed-Refractory Acute Lymphoblastic Leukemia: Results of a Phase II Study. Blood 140(Supp.1), 2022.
45. Haddad FG, Kantarjian H, Short NJ, Konopleva M, Jain N, Huang X, Ravandi F, Wierda W, Borthakur G, Sasaki K, Issa G, Alvarado Y, Pemmaraju N, Garcia-Manero G, Thankachan J, Garris R, Jabbour E. Updated Results from the Phase II Study of Blinatumomab in Combination With Ponatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Clinical Lymphoma Myeloma and Leukemia 22(Supp. 2):S204, 2022.
46. Haddad F, Jabbour E, Issa G, Garcia-Manero G, Ravandi F, Kadia T, Cortes J, Konopleva M, Pemmaraju N, Alvarado T, Yilmaz M, Borthakur G, DiNardo C, Jain N, Daver N, Short N, Kantarjian H, Sasaki K. Treatment-free Remission (TFR) in Patients With Chronic Myeloid Leukemia (CML) Following the Discontinuation of Tyrosine Kinase Inhibitors. Journal of Clinical Oncology 40(Supp. 16):7050-7050, 2022.
47. Haddad F, Sasaki K, Abuasab T, Venugopal S, Rivera D, Bazinet A, Babakhanlou R, Kim K, Senapati J, Ong F, Desikan S, Short N, Pemmaraju N, Borthakur G, DiNardo C, Daver N, Jabbour E, Garcia-Manero G, Ravandi F, Kadia T. Outcomes of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and Hyperleukocytosis. Journal of Clinical Oncology 40(Supp 16):19029-19029, 2022.
48. Haddad F, Kantarjian H, Short N, Ravandi F, Jain N, Macaron W, Kadia T, Alvarado Y, Daver N, Borthakur G, DiNardo C, Konopleva M, Wierda W, Jacob J, Roy E, Loiselle C, Milton A, Rivera J, Garris R, Jabbour E. Mini-hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed B-cell Acute Lymphoblastic Leukemia: Updates From a Phase II Trial. EHA Library, 2022.
49. Macaron W, Kantarjian HM, Short NJ, Ravandi F, Jain N, Kadia TM, Haddad F, Alvarado Valero Y, Daver NG, Borthakur G, Dinardo CD, Konopleva M, Wierda WG, Jacob J, Roy E, Loiselle C, Milton A, Rivera J, Garris R, Jabbour E. Updated results from a phase II study of mini-hyper-CVD (mini-HCVD) plus inotuzumab ozogamicin (INO), with or without blinatumomab (Blina), in older adults with newly diagnosed Philadelphia chromosome (Ph)-negative B-cell acute lymphoblastic leukemia (ALL). Journal of Clinical Oncology 40(Supp. 16):7011-7011, 2022.
50. Haddad F, Sasaki K, Abuasab T, Venugopal S, Rivera D, Bazinet A, Babakhanlou R, Kim K, Senapati J, Ong F, Desikan S, Short N, Pemmaraju N, Borthakur G, DiNardo C, Daver N, Jabbour E, Garcia-Manero G, Ravandi F, Kadia T. Outcomes of patients with newly diagnosed acute myeloid leukemia (AML) and hyperleukocytosis. EHA Library, 2022.
51. Haddad F, Kantarjian H, Jabbour E, Short N, Bidikian A, Ning J, Xiao L, Pemmaraju N, Marx K, Ravandi F, Sasaki K, Issa G. Association between bariatric surgery and outcomes in patients with chronic myeloid leukemia treated with oral tyrosine kinase inhibitors. EHA Library, 2022.
52. Eid R, Hage S, Antonios I, Moussa R, Khoury M, Haddad F, Kourie HR, Kesrouani C, Ghorra C, Abadjian G, Kattan J. Epidemiologic and histologic characteristics of central nervous system lesions: A 20-year experience of a single institution in Lebanon. Journal of Clinical Oncology, 2022.
53. Kaddoum R, Eid R, Haddad F, Germanos M, Mehawej C, Kourie HR, Kattan J. The results of 3000 Fit: A prospective study led at Saint Joseph University of Beirut. Journal of Clinical Oncology, 2022.
54. Ajami J, Jalkh N, Moubarak G, Eid R, Haddad F, Kattan J, Ghosn M, Atallah D, Choueiry E, Kourie HR. Results of NGS panel of hereditary breast and ovarian cancer in Lebanese women. Journal of Clinical Oncology, 2022.
55. Kattan J, Haddad F, Kourie HR, Naderi S, Rassy M, Karak F, Ghosn M, Ghorra C. EGFR mutation incidence and characteristics in non-squamous lung carcinoma in the Lebanese population. Journal of Clinical Oncology, 2022.
56. Haddad F, Kantarjian H, Jabbour E, Issa G, Garcia-Manero G, Ravandi F, Ferrajoli A, Kadia T, Konopleva M, Pemmaraju N, Takahashi K, Alvarado Y, Yilmaz M, Borthakur G, DiNardo C, Jain N, Daver N, Short N, Pierce S, Cortes J, Sasaki K. Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Following the Discontinuation of Tyrosine Kinase Inhibitors. Blood 138(Supp. 1):1480, 2021.
57. Haddad F, Kantarjian H, Short N, Sasaki K, Ravandi F, Kebriaei P, Huang X, Jain N, Konopleva M, Garcia-Manero G, Champlin R, Kadia T, Takahashi K, Daver N, Khoury J, Jorgensen J, Wang S, Khouri M, Jacob J, Garris R, O’Brien S, Jabbour E. Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. Blood 138(Supp. 1):3363, 2021.
58. Sasaki K, Jabbour E, Issa G, Naqvi K, Skinner J, Anderson K, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Garcia-Manero G, Takahashi K, Burger J, Borthakur G, Pemmaraju N, Haddad F, Khoury M, Paul S, Pierce S, Cortes J, Kantarjian H. Low-dose Dasatinib 50 mg/day versus Standard-dose Dasatinib 100 mg/day as Frontline Therapy in Chronic Myeloid Leukemia in Chronic Phase: A Propensity Score Analysis. Blood 138(Supp 1), 2021.
59. Hammond D, Sasaki K, Geppner A, Haddad F, Mohamed S, Rivera D, Siddiqui M, Alwash Y, Perez JR, Morita K, Kim K, Pierce S, Gutierrez C, Pemmaraju N, Borthakur G, Dinardo CD, Ravandi F, Garcia-Manero G, Kantarjian HM, Kadia TM. Contemporary outcomes for adults with AML requiring ICU admission. Journal of Clinical Oncology 39(Supp. 15):7025-7025, 2021.
60. Eid R, Lilly E, Haddad F, Kesserouani C, Kourie HR, Khaddage A, Moubarak M, Atallah D. Characteristics of ovarian tumors in lebanon: 20 years of experience in a lebanese tertiary center. International Journal of Gynecologic Cancer EP787, 2019.
61. Eid R, Abdo M, Zgheib G, Zeidan T, Haddad F, Khaddage A, Kourie HR, Moubarak M, Atallah D. Ovarian metastases from breast cancer: series over a 20-years period at a Lebanese tertiary care center. International Journal of Gynecologic Cancer EP221, 2019.
62. Eid R, Lilly E, Haddad F, Kesserouani C, Kourie HR, Khaddage A, Moubarak M, Atallah D. Characteristics of ovarian tumors in lebanon: 20 years of experience in a lebanese tertiary center. International Journal of Gynecologic Cancer 281, 2019.
63. Eid R, Abdo M, Zgheib G, Zeidan T, Haddad F, Khaddage A, Kourie HR, Moubarak M, Atallah D. Ovarian metastases from breast cancer: series over a 20-years period at a lebanese tertiary care center. International Journal of Gynecologic Cancer 282, 2019.

Book Chapters

1. Haddad F, Daver N. An Update on Immune Based Therapies in Acute Myeloid Leukemia: 2021 and Beyond!. In: Adv Exp Med Biol, 273-295, 2021.